---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-002083"
form_type: "8-K"
ticker: null
cik: "0001029125"
company_name: "Panbela Therapeutics, Inc."
filed_at: "2024-01-25T23:59:59+00:00"
generated_at: "2026-06-06T17:17:29.355918+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Panbela faces Nasdaq delisting over public float shortfall; ASPIRE trial enrollment >50%

## Summary
- Nasdaq staff notified Panbela that after 1-for-20 reverse split on Jan 18, publicly held shares fell below 500,000 minimum.
- Delisting hearing scheduled for bid price and equity compliance; this additional non-compliance basis will be considered by panel.
- Common stock remains listed on Nasdaq Capital Market pending hearing outcome; no assurance of continued listing.
- ASPIRE global phase 3 trial for ivospemin in metastatic pancreatic cancer exceeded 50% enrollment; interim data expected mid-2024.
- Full enrollment projected by Q1 2025; trial has about 90 sites across US, Europe, Australia, and South Korea.

## SEC filing metadata
- accession: 0001437749-24-002083
- form_type: 8-K
- cik: 0001029125
- company_name: Panbela Therapeutics, Inc.
- filed_at: 2024-01-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/0001437749-24-002083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/pbla20240124_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-002083
- JSON: https://secwatch.observer/filing/0001437749-24-002083.json
- Plain text: https://secwatch.observer/filing/0001437749-24-002083.txt

## Key facts
- Listing & Compliance Notices
  Panbela Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5550(a)(4)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5550(a)(4)
  source text: January 22, 2024, Panbela Therapeutics, Inc. (the “Company”) received a notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as of effective date of the previously reported 1-for-20 reverse stock split on January 18, 2024, the Company was no longer in compliance with Nasdaq Listing Rule 5550(a)(4) (the “Minimum Float Requirement”), which requires a minimum of 500,000 publicly held shares. The Staff informed the Company that this matter serves as an additional basis for delisting the Company’s common stock and that the Nasda
  evidence_url: https://www.sec.gov/Archives/edgar/data/1029125/000143774924002083/0001437749-24-002083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.